Why MNC Pharma Still Moans Over Indian IP Ecosystem?

Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this … Continue reading

Prescription Digital Therapy Now A Reality

The pursuit of offering ‘prescription digital therapeutics’ or ‘digiceuticals’ by Big Pharma, to ensure better clinical outcomes for patients, has apparently come to fruition now. On April 18, 2018, by a media release, Novartis announced that the Sandoz Division of the Company … Continue reading

Organic and Inorganic Growth Strategy For Sustainable Business Excellence

For an enthusiast, witnessing any organization growing consistently, is indeed exhilarating. This becomes even more interesting at a time when challenges and frequent surprises in the business environment become a new normal. A robust short, medium and long growth strategy … Continue reading

An Interesting Link: Productivity At Work And Employee Fitness (Part 2)

Part 2: Mental Fitness As I wrote in my previous article, the complex multi-factorial work-life challenges in today’s Volatile, Uncertain, Complex and Ambiguous (VUCA)) world are virtually unprecedented. Interestingly, a sizeable part of such challenge is related to a wide … Continue reading

An Interesting Link: Productivity At Work and Employee Fitness (In 2 Parts)

Part 1: Physical Fitness Today’s work environment is much more challenging than ever before. The challenge is undoubtedly multi-factorial. Many of these are external – mostly related to increasing complex, and difficult to fathom uncertainties and surprises in the overall … Continue reading

Creating A ‘Virtuous Cycle’ Through Patient Reach and Care

As many would know, in the strategic marketing process of any product including patented and generic drugs crafty product differentiation plays a critical role. This strategic process of creating a competitive edge with unique product differentials is necessary. It helps perceiving … Continue reading

‘Rigged’ Payment System Limits Biosimilar Access

As often discussed, market entry of biosimilars, in general, brings a new hope not just for many patients, but also to biosimilar drug manufacturers – planning to get marketing approvals of these drugs in the United States, the El Dorado … Continue reading

‘Made-to-Measure’ Marketing for ‘Made-to-Measure’ Medicines

We have entered into a new era of innovation in medical science where ‘one size fits all’ type of treatment is making a sizeable space for a new ‘made-to-measure’ variety of the same. Such medicines are being developed particularly for … Continue reading